Slide
Sharing
Connections

November 7, 2024

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

October 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

September 17, 2024

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

September 3, 2024

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

August 1, 2024

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

July 31, 2024

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

July 9, 2024

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

June 12, 2024

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

June 11, 2024

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

May 29, 2024

Athira Pharma to Participate in Upcoming June Conferences

May 17, 2024

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 15, 2024

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 2, 2024

Athira Pharma to Participate in Upcoming May Conferences

April 15, 2024

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

April 11, 2024

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

April 3, 2024

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

March 8, 2024

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

February 22, 2024

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

February 8, 2024

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

January 8, 2024

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

January 3, 2024

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

December 12, 2023

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

November 29, 2023

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

November 28, 2023

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

November 15, 2023

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

More News